A matrix tool to foster patient engagement in children, adolescents and young adults: report from a multistakeholder workshop

Le résumé fourni par la source

Patient engagement has become increasingly important in drug development, yet structured guidance to engage children (2–11 years old), adolescents (12–17 years old), and young adults (18–24 years old) is lacking. This study aims to create a matrix tool to foster paediatric patient engagement in drug development by hosting a multistakeholder workshop. A matrix tool was co-developed by the study team and the expert group to provide a framework for paediatric patient engagement across drug development stages. The matrix tool’s concept was evaluated using a Delphi-based approach. A pre-workshop questionnaire was sent to 55 experts, followed by an online multistakeholder workshop with 38 participants. A post-workshop questionnaire was redistributed to the initial participants refine the matrix tool further. The pre-workshop questionnaire (34 respondents) confirmed the need for a co-developed matrix tool, with all statements reaching consensus (cut-off 70% consensus). The workshop (38 participants) revealed strong agreement (92%) on the necessity of such a matrix tool. Participants emphasized the importance of including both chronic and acute diseases, considering patient trial experience, involving families and patient organizations, and aligning age group categories with regulations. The post-workshop questionnaire (18 respondents) showed 89% agreement on involving children, adolescents, and young adults in the matrix tool’s co-development. However, opinions varied on the appropriate minimum age for engagement, ranging from 2 to 17 years. This study presents the initial steps towards developing a matrix tool to enhance paediatric patient engagement in drug development. The multistakeholder approach provided valuable insights into the matrix tool’s structure and content. While further validation and refinement are needed, particularly regarding practical implementation and global applicability, this initiative lays the groundwork for more effective and inclusive paediatric drug development processes. Future research should focus on validating the matrix tool across different age groups and disease contexts, incorporating real life experiences, and addressing cultural and linguistic considerations. This study aimed to create a matrix tool to help involve children, adolescents, and young adults in developing new medicines. Researchers worked with experts from different backgrounds, including patients, doctors, and drug companies, to design this matrix tool. The team first sent out a survey to 55 experts, including patients, asking if such a matrix tool was needed. Most agreed it was. They then held an online workshop with 38 people to discuss the matrix tool’s design. Participants felt it was important to include both long-term and short-term illnesses, consider patients’ experiences with clinical trials, and involve families and patient groups. After the workshop, another survey was sent out to refine the matrix tool further. Most people agreed that involving young patients in developing further the matrix tool would be valuable. However, there were different opinions on what age young children should be when they start getting involved. While this study is a good start, more work is needed to make sure the matrix tool works well in different countries and for various illnesses. Future research should focus on testing the matrix tool with different age groups and types of diseases, and making sure it respects cultural differences. Overall, this matrix tool aims to improve how children and young people are involved in creating new medicines, making the process more inclusive and effective.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.